Primary medication nonadherence is a widespread public health problem; however, the subject lacks standardized definitions and measures.
Primary medication nonadherence is a widespread public health problem; however, the subject lacks standardized definitions and measures making it difficult to establish the true extent of the problem and track changes over time.
In a study published in Journal of Managed Care and Specialty Pharmacy (JMCP) Alex Adams, PharmD, MPH, and Samuel Stolpe, PharmD, compiled set parameters for a new industry measure.
Study Objectives
Primary and secondary nonadherence are distinct subsets of medication non-adherence.
Since most medication adherence research to date has focused on secondary non-adherence, PMN has been identified as a major research gap. There are lack of standardized measures and limited understanding of its true extent. Adams and Stolpe have tried to establish more standardized PMN measures so that it might be helpful in benchmarking and quality improvement initiatives.
For the study, a literature review was conducted using Google Scholar and PubMed databases, covering the time period from 1990 to June 2015. Search terms included “primary non-adherence,” “primary medication non-adherence,” “medication non-redemption,” “medication non-fulfillment,” “primary non-compliance,” “first-fill prescriptions,” and “newly initiated drug therapy.”
Clarity on Terminology
The most frequently used terms (in 77% of all studies) to describe PMN were “primary medication nonadherence” or “primary adherence.” Three studies used the term “prescription abandonment” for the same. But PMN is not the same as prescription abandonment. “Prescription abandonment” is traditionally used in studies as a broader term than PMN and occurs whenever a prescription is filled by a pharmacy but not claimed by the patient.
“PMN occurs when a new medication is prescribed for a patient, but the patient does not obtain the medication, or appropriate alternative, within an acceptable period of time after it was prescribed,” the authors wrote.
Standardization Leads to Effectiveness
Poor medication adherence is an increasing public health issue that has been linked to worse health outcomes, increased hospitalizations, and increased health care costs. Medication nonadherence is responsible for a cost of $290 billion annually in the United States.
It is very important to develop a consensus-based definition and quality measure of PMN. Doing that would enable one step closer towards consistent measurement of this phenomenon. Especially since e-prescribing is becoming the leading mode of prescription transmission, it is important to have standardized methods of tracking PMN in order to study the effectiveness of interventions to reduce PMN.
HOPE-CAT Can Identify Maternal Cardiovascular Risk 2 Months Earlier Than Doctors, Study Says
April 25th 2024In a retrospective study, the machine learning tool was able to screen for potential risks of cardiovascular disease nearly 60 days before the patient's medical record showed any signs of a related condition or before they were officially diagnosed or treated for it.
Read More
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Empowering Community Health Through Wellness and Faith
April 23rd 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In the third episode, Camille Clarke-Smith, EdD, MS, CHES, CPT, discusses approaching community health holistically through spiritual and community engagement.
Listen
Data Back Neoadjuvant Combo vs Chemo Alone for Early-Stage NSCLC
April 24th 2024For patients with early-stage non–small cell lung cancer (NSCLC), combining neoadjuvant immune checkpoint inhibitors and platinum-based chemotherapy improves 2-year outcomes over chemotherapy alone, suggest findings of an extensive literature review and meta-analysis.
Read More